News
ABIO
--
0.00%
--
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
BRIEF-Arca Biopharma Announces First Quarter 2021 Financial Results
reuters.com · 05/11 21:01
ARCA biopharma Q1 EPS $(0.33) Up From $(0.83) YoY
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.33) per share. This is a 60.24 percent increase over losses of $(0.83) per share from the same period last year.
Benzinga · 05/11 20:41
ARCA biopharma reports Q1 results
ARCA biopharma (ABIO): Q1 GAAP EPS of -$0.33.Cash and cash equivalents of $66.93M.Press Release
Seekingalpha · 05/11 20:31
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate u...
GlobeNewswire · 05/11 20:15
10-Q: ARCA BIOPHARMA, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Management's Discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/11 20:08
-- Earnings Flash (ABIO) ARCA BIOPHARMA Posts Q1 Loss $-0.33
MT Newswires · 05/11 16:26
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 05/11 15:05
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
BRIEF-Christopher Graybill Joins Arca As Vice President, Clinical Development
reuters.com · 05/05 21:37
Christopher Graybill Joins ARCA as Vice President, Clinical Development
WESTMINSTER, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a...
GlobeNewswire · 05/05 20:05
ARCA biopharma Taps C. Jeff Dekker for Finance Chief
MT Newswires · 05/04 06:39
BRIEF-Arca Biopharma Announces C. Jeff Dekker To Be Appointed CFO
reuters.com · 05/03 20:58
ARCA Biopharma names Jeff Dekker as chief financial officer
ARCA biopharma (ABIO) announces the appointment of Jeff Dekker as the company's chief financial officer, effective May 10, 2021.The appointment follows Brian Selby’s planned departure from the role after 14 years of service
Seekingalpha · 05/03 20:33
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically ...
GlobeNewswire · 05/03 20:30
BRIEF-Arca Biopharma - May Sell Additional Shares Worth Up To $50 Million
reuters.com · 04/06 21:26
Atrial Fibrillation Market Growth 2021, By Size, Share, Trends Evaluation, Global Growth, Consumption, Consumer-Demand, Recent Developments, Key Strategies, Market Impact and Forecast till 2026
Apr 06, 2021 (The Expresswire) -- Global “Atrial Fibrillation Market” research report offers qualitative and quantitative insights in terms of Atrial...
The Express Wire · 04/06 10:04
The impact of COVID-19 on Atrial Fibrillation Drugs Market - Growth, Trends, Industry Outlook, Growth Opportunity, Business Growth And Forecast (2021 - 2026)
Apr 05, 2021 (The Expresswire) -- The Atrial Fibrillation Drugs market report provides a detailed analysis of global market size, regional and country-level...
The Express Wire · 04/05 04:42
BRIEF-Arca Biopharma Inc Files For Mixed Shelf Of Up To $150 Mln
reuters.com · 03/22 22:09
Webull provides a variety of real-time ABIO stock news. You can receive the latest news about ARCA BIOPHARMA through multiple platforms. This information may help you make smarter investment decisions.
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.